RA Capital Management’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-1,500,000
Closed -$15M – 71
2022
Q4
$15M Hold
1,500,000
– – 0.3% 47
2022
Q3
$14.6M Hold
1,500,000
– – 0.31% 55
2022
Q2
$14.5M Hold
1,500,000
– – 0.39% 52
2022
Q1
$14.6M Hold
1,500,000
– – 0.32% 65
2021
Q4
$14.7M Hold
1,500,000
– – 0.26% 66
2021
Q3
$14.7M Buy
+1,500,000
New +$14.8M 0.2% 68

Other funds holding DALS

RA Capital Management's DALS Position: Q1 2023 in Review

RA Capital Management sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q1 2023, closing a stake of 1,500,000 shares — an estimated $15M sold.

RA Capital Management first reported a position in DALS in Q3 2021 and held it in 6 quarters. The position peaked at $15M in Q4 2022. 50 funds tracked by Wall St. Rank hold DALS as of Q1 2023.

  • RA Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q1 2023 after selling out during the quarter.
  • RA Capital Management sold 1,500,000 DA32 Life Science Tech Acquisition Corp shares in Q1 2023, an estimated $15M.
  • RA Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp in Q3 2021 and held it in 6 quarters.
  • RA Capital Management's DA32 Life Science Tech Acquisition Corp position peaked at $15M in Q4 2022.
  • 50 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q1 2023.

Based on RA Capital Management's 13F filing for Q1 2023, filed 15 May 2023.